ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Gene Expression"

  • Abstract Number: 0644 • ACR Convergence 2022

    Long-lived Plasma Cells in the Lupus Bone Marrow Are Imprinted by Interferon

    Jennifer Barnas1, Diana Alzamareh2, Neha Nandedkar-Kulkarni2, Jennifer Albrecht2, Nida Meednu2, Cameron Baker2, Andrew McDavid1 and Jennifer Anolik2, 1University of Rochester, Rochester, NY, 2University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Systemic lupus erythematous (SLE) is a complex autoimmune disorder with heterogeneous disease presentation and a multi-pronged pathogenesis. Although autoreactive plasma cells (PC) play a…
  • Abstract Number: 1683 • ACR Convergence 2022

    Malondialdehyde-Acetaldehyde (MAA) Modified Matrix Gla Protein (MGP) Increases Citrullination by Human Macrophages

    Spencer Jones1, nozima Aripova1, Michael Duryee1, Austin Ragland1, Bryant England1, Ted Mikuls2 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Malondialdehyde and acetaldehyde, by-products of lipid peroxidation, react with free amino groups on proteins to form a stable post-translational modification (PTM), termed MAA. MAA…
  • Abstract Number: 0486 • ACR Convergence 2022

    Gene Expression Profile of Temporal Artery Tissue and Whole Blood in Giant Cell Arteritis

    Marcia Friedman1, Daniel Albert2, Dongseok Choi3, Hillary Stiefel2, Colin Oglesbee-Venghaus2, Kimberly Ogle2, Christina Harrington4, David Wilson2 and James T. Rosenbaum5, 1Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR, 2Casey Eye Institute, Portland, OR, 3OHSU-PSU School of Public Health, Portland, OR, 4Oregon Health & Science University, Portland, OR, 5Legacy Devers Eye Institute, Portland, OR

    Background/Purpose: Diagnosing giant cell arteritis GCA is notoriously challenging, as there are no reliable blood biomarkers and temporal artery biopsy (TAB) has a sensitivity of…
  • Abstract Number: 0647 • ACR Convergence 2022

    Transcriptomic Analysis of Lupus Nephritis Kidneys Identifies Molecular Endotypes

    Kathryn Kingsmore Allison1, Sneha Shrotri1, Prathyusha Bachali2, Nan Shen3, Amrie Grammer4 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2AMPEL BioSolutions, Redmond, WA, 3Shanghai Jiang Tong University School of Medicine, Shanghai, China, 4AMPEL LLC, Charlottesville, VA

    Background/Purpose: Predicting the course or response to treatment of lupus nephritis (LN) from standard renal biopsies is problematic. We, therefore sought to understand the molecular…
  • Abstract Number: 1686 • ACR Convergence 2022

    Post-translational Modification of Matrix-gla Protein with Malondialdehyde-Acetaldehyde Alters Cellular Responses by Human Fibroblasts

    Austin Ragland1, Michael Duryee1, nozima Aripova1, Spencer Jones1, Ted Mikuls2 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Post-translational modifications with malondialdehyde-acetaldehyde (MAA) alter protein structure and function, inducing pro-inflammatory and pro-fibrotic responses characteristic of rheumatoid arthritis (RA). Matrix-gla protein (MGP) chelates…
  • Abstract Number: 0508 • ACR Convergence 2022

    Detecting the Critical Factors in the Pathogenesis of Anti-melanoma Differentiation-associated Gene 5–positive Dermatomyositis (MDA5 DM) by Gene Expression Analysis of Peripheral Blood

    Yoshinobu Koyama1, Yoshiharu Sato2, Yu Nakai1 and Moe Sakamoto1, 1Japanese Red Cross Okayama Hospital, Okayama, Japan, 2DNA Chip Research Inc, Tokyo, Japan

    Background/Purpose: MDA5 DM is a distinct subtype of DM that is characterized by high mortality due to rapid progressive interstitial lung disease (ILD). MDA5 is…
  • Abstract Number: 0664 • ACR Convergence 2022

    Development of a Novel Gene Expression-based Molecular Score That Characterizes Individual Lupus Patients

    Prathyusha Bachali1, Erika Hubbard2, Kathryn Kingsmore Allison2, Yisha He2, Amrie Grammer3 and Peter Lipsky2, 1AMPEL BioSolutions, Redmond, WA, 2AMPEL BioSolutions, Charlottesville, VA, 3AMPEL LLC, Charlottesville, VA

    Background/Purpose: Patients with SLE can exhibit considerable clinical heterogeneity. A robust patient stratification approach can help to characterize individual lupus patients more effectively based on…
  • Abstract Number: 1687 • ACR Convergence 2022

    A Core Inflammation Program Conserved Across Human and Murine Neutrophils

    Nicolaj hackert1, Felix Radtke1, Tarik Exner1, Carsten Müller-Tidow1, Hanns-Martin Lorenz1, Peter Nigrovic2, Guido Wabnitz1 and Ricardo Grieshaber-Bouyer1, 1Heidelberg University Hospital, Heidelberg, Germany, 2Boston Children's Hospital, Boston, MA

    Background/Purpose: Neutrophils mediate a range of homeostatic and inflammatory processes and display substantial phenotypic and functional heterogeneity. While animal models enable important mechanistic discoveries, differences…
  • Abstract Number: 0519 • ACR Convergence 2022

    Myeloablation Followed by Hematopoietic Stem Cell Transplantation Leads to Long-term Normalization of Systemic Sclerosis Molecular Signatures

    Nancy Wareing1, Xuan Wang2, Lynette Keyes-Elstein3, Ellen Goldmuntz4, Marka Lyons5, Peter McSweeney6, Daniel Furst7, Richard Nash6, Leslie Crofford8, Beverly Welch9, Ashley Pinckney10, Maureen Mayes11, Keith Sullivan12 and Shervin Assassi13, 1UTHealth Houston McGovern Medical School, Houston, TX, 2Baylor Institute for Immunology Research, Dallas, TX, 3Rho, Chapel Hill, NC, 4NIAID/ NIH, Washington, DC, 5University of Texas McGovern Medical School at Houston, Houston, TX, 6Colorado Blood Cancer Institute, Denver, CO, 7University of California Los Angeles, Los Angeles, CA, 8Vanderbilt University Medical Center, Nashville, TN, 9NIAID/NIH, Bethesda, MD, 10Rho, St. Louis Park, MN, 11Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, 12Duke University, Durham, NC, 13McGovern Medical School, University of Texas, Houston, TX

    Background/Purpose: In the randomized Scleroderma: Cyclophosphamide Or Transplantation (SCOT trial), normalization of systemic sclerosis (SSc) peripheral blood gene expression signatures at the 26-month visit was…
  • Abstract Number: 0935 • ACR Convergence 2022

    Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to CsDMARDs, Enriching CsDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy

    Giorgio CASABURI, Tyler O'Malley, Todd Holscher and Ming-Chou Lee, Exagen, Inc., Vista, CA

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease, affecting the joints with varying severity. RA affects approximately 0.5/1% of adults in the…
  • Abstract Number: 1716 • ACR Convergence 2022

    The Transcriptomic Landscape of Nephritic Kidneys Reveals Mechanisms for End Organ Resistance to Damage in Lupus-prone Mice

    Andrea Daamen1, Hongyang Wang2, Prathyusha Bachali3, Shu Man Fu2, Amrie Grammer4 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2University of Virginia, Charlottesville, VA, 3AMPEL BioSolutions, Redmond, WA, 4AMPEL LLC, Charlottesville, VA

    Background/Purpose: Pathologic inflammation is a major driver of kidney damage in lupus nephritis (LN), but the immune mechanisms of disease progression and risk factors for…
  • Abstract Number: 0528 • ACR Convergence 2022

    Nasal Epithelial Gene Expression Profiling Preceding Relapse in Patients with Granulomatosis with Polyangiitis

    Fang R. Zhao1, Rebecca Deek2, James Garifallou3, Jalal Jalaly2, Cailu Lin4, Danielle Reed4, Shubhasree Banerjee2, Naomi Amudala2, Antoine Sreih5, Sherry Chou2, Virginia Livolsi2, Ronald Collman2, Hongzhe Lee2, Peter Merkel2, Peter Grayson6, Noam Cohen2, Jonathan Miner2 and Rennie Rhee2, 1Washington University in St. Louis, St. Louis, MO, 2University of Pennsylvania, Philadelphia, PA, 3Children's Hospital of Philadelphia, Philadelphia, PA, 4Monell Center, Philadelphia, PA, 5Bristol Myers Squibb, Philadelphia, PA, 6National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Predicting relapse is a major challenge in granulomatosis with polyangiitis (GPA). We previously demonstrated changes in the nasal microbiota, particularly Corynebacterium tuberculostearicum, prior to…
  • Abstract Number: 0984 • ACR Convergence 2022

    Impact of Hydroxychloroquine on Interferon Pathway Expression of SLE Phenotypic Subsets in the Absence of Background Medications

    Colin Mowery, Miles Smith, Kevin Thomas, Susan Macwana, Wade deJager, Stan Kamp, Cristina Arriens, Teresa Aberle, Judith James, Joel Guthridge and Joan Merrill, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Chronic activation of interferon (IFN) pathways is a key driver of immune dysregulation in SLE. Hydroxychloroquine (HCQ) inhibits toll-like receptors 7 and 9 in…
  • Abstract Number: 1736 • ACR Convergence 2022

    IL-23 Signaling Induces Autoimmune Disease Genes in Mucosal-Associated Invariant T Cells

    Tharshana Stephen1, Ambre Dangien1, Claire Leloup1, Ikram Mezghiche1, Laetitia Camard1, Hanan Yahia-Cherbal1, Vincent Guillemot2, Natalia Pietrosemoli1, Hélène Lopez-Maestre1, Julie Marsande1, Milena Hasan1, Dan Cua3, Anne Fourie4, Carrie Greving5, Raphaelle Parker6, Barbara Joyce Shaikh7, Bénédicte Oulès8, Sarah Guégan8, Sélim Aractingi8, Elisabetta Bianchi1 and Lars Rogge1, 1Institut Pasteur, Paris, France, 2Institut Pasteur, Paris, Ile-de-France, France, 3Janssen Research and Development, LLC, Spring House, PA, 4Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, CA, 5Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, 6Janssen Research & Development, Janssen-Cilag, Paris, France, 7Janssen Research & Development, LLC, San Diego, CA, 8Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Genome-wide association studies and mouse models of autoimmune disease have demonstrated an important role of the IL-23 signaling pathway in the pathogenesis of axial…
  • Abstract Number: 0547 • ACR Convergence 2022

    Profiling of Systemic Immune Responses in Axial Spondyloarthritis Patients Reveals Strikingly Distinct Cellular and Molecular Mechanisms of Action of IL-17A Inhibitors and TNF-Blockers

    Nicolas Rosine1, Surya Koturan1, Vincent Guillemot2, Claire Leloup1, Fanni Veress1, Tharshana Stephen1, Hanan Yahia-Cherbal1, Jérémie SELLAM3, Francis Berenbaum4, Natalia Pietrosemoli1, Elisabetta Bianchi1, Corinne MIceli5 and Lars Rogge1, 1Institut Pasteur, Paris, France, 2Institut Pasteur, Paris, Ile-de-France, France, 3Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, 4Sorbonne University - Saint-Antoine hospital, Paris, France, 5APHP, Paris, France

    Background/Purpose: IL-17A inhibitors (IL-17i) and TNF-inhibitors (TNFi) are currently the only biologic drugs available to treat axial spondyloarthritis (axSpA). While several studies have provided mechanistic…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 33
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology